Compound library/Primary-source evidence guide

CJC-1295 + Ipamorelin Blend

Combination-product claims, component evidence, and the absence of blend-specific proof

CJC-1295 plus ipamorelin is marketed as a growth-hormone secretagogue blend. Evidence for individual components, hormone-response endpoints, or mechanistic synergy does not automatically establish safety, effectiveness, or product quality for an unapproved combination vial.

Editorial status

This page aggregates regulatory documents and published human research. Its claims, citations, populations, and limitations received an independent editorial evidence check. Last editorial audit: .

It has not been medically reviewed by a clinician. It provides general education, not diagnosis, treatment, dosing instructions, or advice for an individual. Use the product-specific official information and consult a qualified clinician or pharmacist for personal decisions.

Product and regulatory distinctions

A compound name is not one interchangeable set of instructions. Product, formulation, indication, labeling, and jurisdiction matter.

CJC-1295 + ipamorelin blend

This guide does not identify a current FDA-approved combination drug product for this blend.

Current source

Compounded or online blends

Compounded products are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality.

Current source

Sport context

Growth-hormone secretagogues and releasing factors can raise anti-doping issues for covered athletes.

Current source

Claim-by-claim evidence map

Each finding is tied to the population and product actually studied. Trial results are not personal predictions.

Randomized human trial

CJC-1295 increased GH and IGF-1 in short clinical-pharmacology studies of healthy adults.

Population
Healthy adults aged 21 to 61 in two randomized, placebo-controlled, double-blind, ascending-dose trials.
Finding
Single and repeated CJC-1295 doses produced sustained, dose-dependent increases in measured GH and IGF-1 concentrations.
Limits
These were short component studies focused on pharmacokinetic and hormone-response endpoints, not clinical benefit, long-term safety, or a CJC-1295 plus ipamorelin blend.
Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults
Observational human evidence

Ipamorelin produced a measurable GH response in an early human pharmacology study, while selectivity claims came primarily from animal experiments.

Population
Dose-escalation cohorts of eight healthy male volunteers per infusion level; separate receptor and hormone-selectivity experiments used rat pituitary cells, rats, and swine.
Finding
The human study characterized a brief GH-release episode after infusion; the preclinical study found GH release with no significant ACTH or cortisol increase in swine at the tested exposures.
Limits
The human study did not test clinical outcomes or the blend, and animal selectivity findings cannot establish human safety or benefit.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteersIpamorelin, the first selective growth hormone secretagogue
Unsupported or anecdotal

Blend-specific clinical proof is separate from component rationale.

Population
People considering a combination vial.
Finding
A combined product introduces ratio, purity, stability, sterility, and interaction questions.
Limits
This guide cannot authenticate the blend or recommend a regimen.
Compounded Drugs: Questions and Answers

What this evidence does not answer

  • No FDA-approved blend product or indication is identified here.
  • Blend-specific randomized outcome evidence is not established by component studies.
  • Long-term endocrine, glucose, cancer-history, and interaction risks require clinician review.

Useful information to organize between visits

  • Exact component names, ratio, source, and lot
  • Baseline endocrine or metabolic conditions
  • Concurrent hormones, GLP-1s, sleep medicines, or supplements
  • Symptoms, labs, and clinician follow-up

Questions to bring to a clinician or pharmacist

  1. 1.Is there a diagnosed endocrine indication?
  2. 2.What evidence supports the blend rather than each component separately?
  3. 3.What monitoring would detect harm or unintended hormone changes?

Primary sources

  1. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adultsJournal of Clinical Endocrinology & Metabolism · Published 2006-03 · Accessed July 12, 2026
  2. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteersPharmaceutical Research · Published 1999-09 · Accessed July 12, 2026
  3. Ipamorelin, the first selective growth hormone secretagogueEuropean Journal of Endocrinology · Published 1998-12 · Accessed July 12, 2026
  4. Drugs@FDA: FDA-Approved DrugsU.S. Food and Drug Administration · Published Current database · Accessed July 12, 2026
  5. Compounded Drugs: Questions and AnswersU.S. Food and Drug Administration · Published Current guidance · Accessed July 12, 2026
  6. 2026 Prohibited ListWorld Anti-Doping Agency · Published 2026 · Accessed July 12, 2026

Turn scattered notes into a useful treatment history

Dosi organizes timing, locations, symptoms, reminders, and questions for your next appointment. It does not prescribe or replace your care team.

Start tracking free